2022
DOI: 10.1111/apt.16983
|View full text |Cite
|
Sign up to set email alerts
|

Editorial: chronic DILI and HILI—corticosteroid plus glycyrrhizin as standard therapy? Authors' reply

Abstract: We would like to thank Rolf Teschke and Axel Eickhoff for their interest in our work investigating the efficacy and safety of corticosteroid (CS) plus glycyrrhizin (GC) therapy for chronic drug-or herb-induced liver injury (DILI/HILI). 1,2 Cessation of the suspected agent(s) is widely recommended and convincingly proved to reverse 80% DILI in the acute phase, 3,4 but this strategy seemed not contributable for patients in our study. It is worth to note that all the participants in two groups of this study have … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2023
2023

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 5 publications
0
1
0
Order By: Relevance
“…A positive therapeutic effect was described in a study from China that perfectly used the updated RUCAM with scores ≥6, pre-defined thresholds of ALT and ALP, and exclusion of competing causes in liver injury cases with patients, who were treated with corticosteroids plus glycyrrhizin [202]. In this single-center randomized open-label trial, cases of DILI and HILI cases were included with separate evaluation of the two cohorts and their subgroups in line with CSH guidelines, recommending the use of the updated RUCAM in future trials with more patients, with some open questions that were clarified subsequently [203,204]. This prospective study from China also attracted the interest of another group working on the same topic but used a less straightforward approach [205] compared to the Chinese study [202].…”
Section: Rucam In Search For Pharmacotherapy Options Of Idilimentioning
confidence: 99%
“…A positive therapeutic effect was described in a study from China that perfectly used the updated RUCAM with scores ≥6, pre-defined thresholds of ALT and ALP, and exclusion of competing causes in liver injury cases with patients, who were treated with corticosteroids plus glycyrrhizin [202]. In this single-center randomized open-label trial, cases of DILI and HILI cases were included with separate evaluation of the two cohorts and their subgroups in line with CSH guidelines, recommending the use of the updated RUCAM in future trials with more patients, with some open questions that were clarified subsequently [203,204]. This prospective study from China also attracted the interest of another group working on the same topic but used a less straightforward approach [205] compared to the Chinese study [202].…”
Section: Rucam In Search For Pharmacotherapy Options Of Idilimentioning
confidence: 99%